Carna Biosciences Inc
TSE:4572
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
JP |
Carna Biosciences Inc
TSE:4572
|
7.5B JPY | 1.9 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
223B USD | 4.8 | ||
US |
Danaher Corp
NYSE:DHR
|
185.2B USD | 3.5 | ||
US |
Agilent Technologies Inc
NYSE:A
|
42.3B USD | 6.8 | ||
CH |
Lonza Group AG
SIX:LONN
|
38B CHF | 4 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.5B USD | 6.8 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 5.8 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
27.5B USD | -184.4 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
25.9B USD | 9.8 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.8B USD | 2.7 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 5 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.